US2005153910A1PendingUtilityA1

Antibody and inhibitor and transformation method and transformation kit using the same

Priority: Jun 12, 2002Filed: Feb 17, 2003Published: Jul 14, 2005
Est. expiryJun 12, 2022(expired)· nominal 20-yr term from priority
C07K 16/2896C07K 16/28A61P 31/12A61K 2039/505
51
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides a monoclonal antibody which specifically binds to human Toll-like receptor 3. Further, the present invention provides an inhibitor which (a) suppresses a double-stranded RNA-mediated immune response in a cell which expresses Toll-like receptor recognizing the double-stranded RNA and produces type I interferon, and (b) includes an antibody, which binds to the Toll-like receptor and inhibits production of the type I interferon. Particularly, the antibody is a monoclonal antibody against human Toll-like receptor 3. Further, the present invention provides a transfection method comprising the step of infecting a cell which expresses Toll-like receptor recognizing a double-stranded RNA and produces type I interferon by expressing Toll-like receptor recognizing a double-stranded RNA with a recombined virus vector, in which a gene of interest has been inserted, under the inhibitory condition for production of the type I interferon by using an inhibitor including an antibody which binds to the Toll-like receptor. Thus, it is possible to provide (i) an inhibitor which inhibits the production of the type I interferon induced by a virus double-stranded RNA so as to suppress an immune response against the virus, and (ii) a transfection method or a transfection kit whereby a transfection efficiency is improved without enhancing an infectious capacity of a virus vector.

Claims

exact text as granted — not AI-modified
1 . An antibody, specifically binding to human Toll-like receptor 3.  
     
     
         2 . An inhibitor for suppressing a double-stranded RNA-mediated immune response in a cell which expresses a Toll-like receptor recognizing the double-stranded RNA and produces type I interferon, 
 the inhibitor comprising an antibody, which binds to the Toll-like receptor and inhibits production of the type I interferon.    
     
     
         3 . The inhibitor as set forth in  claim 2 , wherein the antibody is a monoclonal antibody against human Toll-like receptor 3.  
     
     
         4 . A transfection method, comprising the step of infecting a cell which expresses a Toll-like receptor recognizing a double-stranded RNA and produces type I interferon with a recombined virus vector, in which a gene of interest has been inserted, under the inhibitory condition for production of the type I interferon by using an inhibitor including an antibody which binds to the Toll-like receptor.  
     
     
         5 . The method as set forth in  claim 4 , wherein the antibody is a monoclonal antibody against human Toll-like receptor 3.  
     
     
         6 . A transfection kit for transfecting a cell which expresses Toll-like receptor recognizing a double-stranded RNA and produces type I interferon, 
 the transfection kit comprising:    an inhibitor including an antibody, which binds to the Toll-like receptor and inhibits production of the type I interferon; and    a recombined RNA virus vector in which a gene of interest has been inserted.    
     
     
         7 . The transfection kit as set forth in  claim 6 , wherein the antibody is a monoclonal antibody against human Toll-like receptor 3.  
     
     
         8 . A method for control production of type I interferon by using an antibody which specifically binds to Toll-like receptor recognizing a double-stranded RNA.

Join the waitlist — get patent alerts

Track US2005153910A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.